Theolytics is a biotechnology company harnessing viruses to combat cancer.

A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population.

In addition to advancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.

Our team are one of the most important elements of who we are and what we do. We combine world leading scientific expertise – encompassing virology, cancer biology, immunology, bioinformatics, and molecular biology – with a track record of translating oncolytic viral therapies into the clinic.

Our Board and Advisory group provide extensive international commercial and therapeutic development expertise.